Bernstein analyst Vincent Chen raised his price target for Alnylam to $135 from $94 after the company announced the positive readout of the patisiran trial, with compelling efficacy, signs of reversing neuropathy, and no safety signals. Combining the increase in probability of success with a market share forecast that increasingly tilts toward Alnylam, and factoring in what is likely considerable pricing power, the analyst now forecasts about $2.7B in risk-adjusted Alnylam TTR amyloidosis sales in 2030, up from $1.5B. He reiterates an Outperform rating on the shares.